Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient

Patent metadata

Field	Value
Publication number	US-10265276-B2
Application number	US-201615564850-A
Country	US
Kind code	B2
Filing date	Apr 8, 2016
Priority date	Apr 9, 2015
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

Disclosed herein is a pharmaceutical composition for treating or preventing inflammatory diseases or arthritis, which includes 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition exhibits superior therapeutic efficacy against arthritis without any side effects such as toxicity, etc.

First claim

What is claimed is:

1. A method for treating STAT3-mediated inflammatory disease comprising administering a therapeutically effective amount of 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol having Formula 1:

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the STAT3-mediated inflammatory disease is selected from the group consisting of septicemia, septic shock, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, vasculitis, pleurisy, pericarditis, ischemic-related inflammation, inflammatory aneurysms, nephritis, hepatitis; chronic pulmonary inflammatory disease, bronchial inflammation, rhinitis, dermatitis, gastritis, colitis, irritable bowel syndrome, fever, myalgia caused by infection or a combination thereof.

3. The method according to claim 1 , wherein the STAT3-mediated inflammatory disease comprises diseases accompanying inflammation caused by an inflammatory mediator selected from the group consisting of NO, iNOS, COX-2, PGE2, TNF-α, ikB, IL-6, and IL-1.

4. A method for treating STAT3-mediated arthritis, the method comprising administering of 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol having Formula 1:

or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4 , wherein the STAT3-mediated arthritis comprises osteoarthritis, rheumatoid arthritis, or pyogenic arthritis.

6. The method according to claim 4 , wherein the STAT3-mediated arthritis comprises diseases accompanying inflammation caused by an inflammatory mediator selected from the group consisting of NO, iNOS, COX-2, PGE2, TNF-α, ikB, IL-6, and IL-1.

Assignees

• Nat Univ Chungbuk Ind Acad Coop Found

Inventors

• Hong Jin Tae
• Lee Hee Pom
• Ham Young Wan
• Kim Chun Sik
• Jung Heon Sang
• Kim Dae Hwan

Classifications

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61K31/045

  Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates · CPC title

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/05 Primary

  Phenols {(cannabinoids A61K31/658)} · CPC title